To see the other types of publications on this topic, follow the link: National Hospital Pharmaceutical Strategy.
Journal articles on the topic 'National Hospital Pharmaceutical Strategy'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 journal articles for your research on the topic 'National Hospital Pharmaceutical Strategy.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
1
Tordoff, June M., Pauline T. Norris, Julia M. Kennedy, and David M. Reith. "Influence of the National Hospital Pharmaceutical Strategy on the Assessment of New Medicines in New Zealand Public Hospitals." Journal of Pharmacy Practice and Research 35, no. 4 (December 2005): 271–75. http://dx.doi.org/10.1002/j.2055-2335.2005.tb00361.x.
Full text
2
Hsu, Edbert B., Julie A. Casani, Al Romanosky, Michael G. Millin, Christa M. Singleton, John Donohue, E. Robert Feroli, et al. "Critical Assessment of Statewide Hospital Pharmaceutical Surge Capabilities for Chemical, Biological, Radiological, Nuclear, and Explosive Incidents." Prehospital and Disaster Medicine 22, no. 3 (June 2007): 214–18. http://dx.doi.org/10.1017/s1049023x00004696.
Full textAbstract:
AbstractIntroduction:In recent years, government and hospital disaster planners have recognized the increasing importance of pharmaceutical preparedness for chemical, biological, radiological, nuclear, and explosive (CBRNE) events, as well as other public health emergencies. The development of pharmaceutical surge capacity for immediate use before support from the (US) Strategic National Stockpile (SNS) becomes available is integral to strengthening the preparedness of local healthcare networks.Methods:The Pharmaceutical Response Project served as an independent, multidisciplinary collaboration to assess statewide hospital pharmaceutical response capabilities. Surveys of hospital pharmacy directors were conducted to determine pharmaceutical response preparedness to CBRNE threats.Results:All 45 acute care hospitals in Maryland were surveyed, and responses were collected from 80% (36/45). Ninety-two percent (33/36) of hospitals had assessed pharmaceutical inventory with respect to biological agents, 92% (33/36) for chemical agents, and 67% (24/36) for radiological agents. However, only 64% (23/36) of hospitals reported an additional dedicated reserve supply for biological events, 67% (24/36) for chemical events, and 50% (18/36) for radiological events. More than 60% of the hospitals expected to receive assistance from the SNS within ≤48 hours.Conclusions:From a pharmaceutical perspective, hospitals generally remain under-prepared for CBRNE threats and many expect SNS support before it realistically would be available. Collectively, limited antibiotics and other supplies are available to offer prophylaxis or treatment, suggesting that hospitals may have insufficient pharmaceutical surge supplies for a large-scale event. Although most state hospitals are improving pharmaceutical surge capabilities, further efforts are needed.
3
Alomi, Yousef Ahmed, Saeed Jamaan Alghamdi, and Radi Abdullah Alattyh. "National Survey of Drug Information Centers practice: Pharmacoeconomic System at Ministry of Health Hospitals in Saudi Arabia." Research in Pharmacy and Health Sciences in Volume 4, Issue 3: July 2018- September 2018 4, no. 3 (September 30, 2018): 503–7. http://dx.doi.org/10.32463/rphs.2018.v04i03.18.
Full textAbstract:
Objective: To explore the National Survey of Drug Information Centers practice in Saudi Arabia: PharmacoEconomic System at Ministry of Health Hospitals. Methods: It is a cross-sectional four months national survey of Drug Information Services at MOH. It contained ten domains with 181 questions designed by the authors. It was derived from Internal Pharmaceutical Federation (FIP), American Society of Health-System Pharmacists best practice guidelines. This survey was distributed to forty hospital pharmacies that run drug information services. In this study, the domain of Pharmacoeconomics System was explored and analyzed. It consisted of eight questions about the written policy and procedure and application methods for the PharmacoEconomic system in the drug information centers. All analysis was done through survey monkey system. Results: The survey was distributed to forty-five of hospitals, the response rate, was 40 (88.88%) hospitals. Of those; The Written policy and procedure of PharmacoEconomic did not exist in 26 (65%) hospitals. The definition types of PharmacoEconomic do not exist in 23 (57.5%) hospitals. Evaluation Processes of PharmacoEconomic Studies did not exist in 22 (55%) hospitals. The intensive analysis performed for all significant potential cost of the medications did not exist in 22(55%) hospitals. The evidence for using reported PharmacoEconomic data to improve medication use process and reduce cost rate, not found in 22 (55%) hospitals. Moreover, the Evidence of involvement of Drug Evaluation Processes not existed in 20 (50%) hospitals. Conclusion: the pharmacoeconomics system was week implementations of drug information centers practice. Revision of pharmacy strategic plan with pharmacoeconomics applications is required to improve the system at MOH hospital in the kingdom of Saudi Arabia.
4
Howard, P. "A survey of national, regional and hospital chief pharmacists on consultant pharmacist appointment strategy and performance in the united kingdom." European Journal of Hospital Pharmacy 19, no. 2 (March 12, 2012): 253.1–253. http://dx.doi.org/10.1136/ejhpharm-2012-000074.441.
Full text
5
Shaydullina, L. Y., and L. E. Ziganshina. "Rational use of medicines: contribution to development of healthcare systems." Kazan medical journal 93, no. 5 (October 15, 2012): 803–6. http://dx.doi.org/10.17816/kmj1715.
Full textAbstract:
Development of World Health Organization (WHO) Rational Use of Medicines concept internationally and its implementation in the Russian Federation is reviewed. The need to consolidate efforts for the introduction of the WHO-developed strategy for the use of medicines improvement is explained. The WHO strategy to improve the use of medicines is described. Abundance of medicines, medicinal products and various formulations of the same active substances, as well as of promotional materials, which often mislead healthcare community and consumers, requires establishment of a system promoting effective and safe use of medicines and ensuring access to essential medicines of all members of the society. The factors which contribute to irrational use of medicines, avoidable causes, and consequences of irrational use of medicines are presented. Current situation in the Russian Federation regarding the use of medicines: legal and regulatory framework, the results of the registration process, documents valid on a national level and in particular regions that determine pharmaceutical policy is described in detail. Methodology of assessing prescribing practices and medicine consumption recommended by the World Health Organization for implementation and use globally is revealed. The implementation of the WHO concept of the rational use of medicines in the Republic of Tatarstan is described as an example. An illustration of the authors’ findings on effects of clinical pharmacology services on containment of medicines’ costs at the level of internal diseases department of municipal hospital is presented. The leading thesis of WHO Rational Use of Medicines concept - the establishment of independent multidisciplinary regional structures responsible for the quality use of medicines - is substantiated.
6
Bamfi, Francesco, Federica Basso, Massimo Aglietta, Carmelo Bengala, Vito Lorusso, Paolo Pronzato, Maria Caterina Cavallo, Orietta Zaniolo, and Sergio Iannazzo. "Budget impact analysis of the use of lapatinib in the treatment of breast cancer in Italy." Farmeconomia. Health economics and therapeutic pathways 10, no. 1 (March 15, 2009): 33–46. http://dx.doi.org/10.7175/fe.v10i1.161.
Full textAbstract:
Objective: to estimate the impact of lapatinib utilization within the Italian National Health Service (NHS) resources consumption. Lapatinib is an oral inhibitor of kinase protein, approved as dual therapy with capecitabine for the treatment of metastatic breast cancer patients with HER2 overexpression who experience disease progression despite trastuzumab treatment. Methods: the analysis is based on a model, which structure can be summarized as follows: a) national cancer registries-based estimate of the yearly number of HER2+ breast cancer patients who develop metastatic disease in Italy; b) literature-based identification of the rate of patients eligible to receive lapatinib; c) identification of the current therapeutic strategy-mix; d) costing of the alternatives, and e) calculation of budget impact. Direct NHS costs (drug acquisition and administration, and monitoring for 8 cycles of 21 days) are estimated based on current Italian prices and tariffs. Results: the annual number of patients eligible for lapatinib-based therapy can vary from 1,676 to 2,172, according to the expected extent of the trastuzumab use as adjuvant therapy. The current strategy-mix beyond progression is based on drugs used in the clinical practice, with a portion of patients continuing trastuzumab. Pharmaceutical cost of lapatinib results higher than the average cost of the current pattern of treatments. This cost increase would be partially offset by the reduction of laboratory tests and hospital personnel work for the oral administration of lapatinib, as compared to intravenous strategies. Furthermore, a risk sharing agreement has been adopted by NHS and manufacturer, according to which the NHS pays only for responding patients. As a consequence, lapatinib-based therapy would increase yearly NHS expenditure by about 3.8-4.9 millions of euro. Conclusions: lapatinib is the only treatment option specifically indicated for the management of HER2+, metastatic breast cancer in patients who received prior treatments including trastuzumab and is estimated to induce a low budget impact for the Italian NHS.
7
Grossman, Stuart A., Louis B. Nabors, Joy D. Fisher, Patrick Y. Wen, William C. Timmer, Frederick G. Barker, David M. Peereboom, et al. "The 1994 National Cancer Institute’s strategy to fund multi-institutional, multidisciplinary consortia to design and conduct early phase clinical trials in patients with high grade gliomas." Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021): 2003. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.2003.
Full textAbstract:
2003 Background: : In the early 1990’s, the NCI suspended activities of the Brain Tumor Study Group seeking to shift clinical brain tumor research from phase III trials to innovative and correlative rich phase I/II studies. In 1994, NCI funded three early phase brain tumor consortia, later reduced to two consortia in 1999 and one in 2009. In 2020, the NCI announced it would discontinue funding the brain tumor consortium and emphasize pre-clinical glioblastoma drug development (RFA-CA-20-047). Methods: The activities of the New Approaches to Brain Tumor Therapy (NABTT: 1994-2009) and Adult Brain Tumor Consortium (ABTC: 2009-2021) were summarized using data from the Central Operations Office that served the consortia for 27 years. Results: From 1994-2020, 48 consortium meetings were held to discuss, develop, conduct, and evaluate early phase clinical trials. These involved multidisciplinary brain tumor experts (neuro-oncologists, neurosurgeons, radiation oncologists, neuropathologists, statisticians, pharmacologists, imaging experts, immunologists, etc) from 27 US academic centers and hospitals. 85 clinical trials were written, approved by NCI and the Brain Malignancy Steering Committee, and conducted. Most trials evaluated NCI-provided therapeutic agents. 34 trials were conducted in collaboration with 27 pharmaceutical companies eager to develop malignant brain tumor therapeutics; for 9 of these the consortia held the IND. 4870 patients were accrued: 3375 to therapeutic and 1495 to non-therapeutic studies. 49 grant proposals were submitted to fund consortium activities with a 46% approval rate. 91 peer reviewed manuscripts were published, with 174 presentations and abstracts. 18 pharmaceutical symposia were conducted to attract new agents toward early phase brain tumor research. Consortia sponsored 34 Guest Lectureships and multidisciplinary symposia to focus on relevant critical research areas. Additionally, the consortia provided unique opportunities for young faculty to lead multicenter NABTT/ABTC trials with appropriate support and mentorship. Conclusions: Therapeutic progress for high grade gliomas has been slow for many reasons (95% of systemically administered agents do not penetrate the blood-brain barrier, inherent treatment resistance, immunologically “cold” phenotype, etc). NABTT/ABTC focused multidisciplinary, multi-institutional experts on major challenges unique to brain tumor research. The consortia developed innovative early phase clinical studies rich in correlative endpoints, fostered research grants, hosted relevant topical symposia, and provided leadership roles for young investigators while bringing together the NCI, industry, and committed multidisciplinary academicians to explore novel therapeutic options for patients with primary brain tumors.
8
Liatsos, C., A. Papaefthymiou, N. Kyriakos, M. Giakoumis, M. Tzouvala, M. Doulberis, C. Mavrogiannis, and J. Kountouras. "P704 The biennial direct pharmaceutical costs per treatment with biologics for the inflammatory bowel disease in Greece: A comparative calculation study." Journal of Crohn's and Colitis 14, Supplement_1 (January 2020): S569—S571. http://dx.doi.org/10.1093/ecco-jcc/jjz203.832.
Full textAbstract:
Abstract Background Inflammatory bowel disease (IBD), as a chronic disease with relatively high prevalence worldwide, has undoubtedly resulted in a notable economic burden on health care systems globally. The IBD treatment with biologics (IBD-BT) seems quite complex with various strategies to induce and maintain remission and balance against long-term complications. IBD-BT costs have never been estimated in detail so far in Greece, especially during such a severe 10-years financial crisis experience. Methods Direct pharmaceutical costs for one and two years, both for induction and maintenance, adult treatment diagnosed with Crohn’s disease (CD-BT) or Ulcerative colitis (UC-BT) were estimated. For intravenous agents, the hospital drug prices and one day admission costs were calculated, whereas for subcutaneous biologics the retail ones. It was taken for granted that all patients were fully responders and after the approved induction scheme continued with the standard maintenance strategy. Prototype and biosimilar drug prices were also assessed where available. More specifically, when considering biosimilars, the most affordable one was included to our analysis. Each drug price was estimated based on the data collected from the 2019 Greek official electronic national publication on drug therapy of the Greek national organisation for medicines. Results Table shows the costs in euros of each IBD-BT scheme. The biosimilar adalimumab was proved as the most affordable choice both for CD- and UC-BT. The second most affordable choice for CD revealed to be the prototype Adalimumab and respectively for UC the recently introduced tofacitinib, in the maintenance dose of 5 mg bid after week 8 (with a slight burden when the more intensive scheme with Tofacitinib 10 mg bid for 16 weeks is necessary). The most expensive strategies include Ustekinumab 90 mg (per 8 weeks for body weight—BW > 55 to ≤85 kg and >85 kg) and the prototype Infliximab 5 mg/kg (per 8 weeks for BW>81 kg), whereas Vedolizumab remains expensive regardless BW. It is worthwhile to mention that the hospitalisation expenditures (563€) raise the costs of intravenous agents when compared with the subcutaneous ones. Conclusion The biennial direct pharmaceutical costs for the approved IBD-BT schemes both for induction and maintenance phases in fully responders were estimated thoroughly for the first time in Greece. These results should motivate Governments and European Union policymakers in order to promote cost-benefit and cost-utility studies to offer the best patients’ benefit by evaluating and deciding the most suitable regimen with respect to biologic prices, adverse effects, hospitalisation expenditures, IBD complications and recurrences.
9
Westerlund, Tommy, and Bertil Marklund. "Community pharmacy and primary health care in Sweden - at a crossroads." Pharmacy Practice 18, no. 2 (May 2, 2020): 1927. http://dx.doi.org/10.18549/10.18549/pharmpract.2020.2.1927.
Full textAbstract:
The overall goal of Swedish health care is good health and equitable care for the whole population. The responsibility for health is shared by the central government, the regions, and the municipalities. Primary care accounts for approximately 20 percent of all expenditures on health care. About 16% of all physicians work in primary health. The regions have also employed a large number of clinical pharmacists, usually hospital-based, but many perform a variety of different primary care services, the most common of which is patient medication reviews. Swedish primary health care is at a crossroads facing extensive challenges, due to changes in demography and demanding financial conditions. These changes necessitate large transformations in health services and delivery. Current Government inquiries have primarily focused on two ways to meet the challenges; a shift towards more local care requiring a transfer of resources from hospital care, and a further development of structured digi-physical care, that is both digital (“online doctors”) and physical accessibility of care. While primary care at present is undergoing processes of change, community pharmacy has done so during the past decade since the re-regulation of the Swedish pharmacy market. A monopoly was replaced by a competitive system, where five pharmacy chains now share most of the market, a competition that has made community pharmacy very commercialized. A number of different, promising primary care services are being offered, but they are usually delivered on a small scale due to a lack of remuneration and philosophy of providers. Priority is given to sales and fast dispensing of prescriptions, often with a minimum of counseling. Reflecting primary health care, community pharmacy in Sweden is at a crossroads but currently has a golden opportunity to choose a route of collaboration with primary health care in its current transformation into more local and digi-physical care. A major challenge is that primary health care inquires, strategic plans, and national policy documents usually do not include community pharmacy as a partner. Hence, community pharmacy have to be proactive and seize this chance of changes in primary health policy and organization in order to become an important link in the chain of health care delivery, or there is a significant risk that it will predominantly remain a retail business.
10
Westerlund, Tommy, and Bertil Marklund. "Community pharmacy and primary health care in Sweden - at a crossroads." Pharmacy Practice 18, no. 2 (May 2, 2020): 1927. http://dx.doi.org/10.18549/pharmpract.2020.2.1927.
Full textAbstract:
The overall goal of Swedish health care is good health and equitable care for the whole population. The responsibility for health is shared by the central government, the regions, and the municipalities. Primary care accounts for approximately 20 percent of all expenditures on health care. About 16% of all physicians work in primary health. The regions have also employed a large number of clinical pharmacists, usually hospital-based, but many perform a variety of different primary care services, the most common of which is patient medication reviews. Swedish primary health care is at a crossroads facing extensive challenges, due to changes in demography and demanding financial conditions. These changes necessitate large transformations in health services and delivery. Current Government inquiries have primarily focused on two ways to meet the challenges; a shift towards more local care requiring a transfer of resources from hospital care, and a further development of structured digi-physical care, that is both digital (“online doctors”) and physical accessibility of care. While primary care at present is undergoing processes of change, community pharmacy has done so during the past decade since the re-regulation of the Swedish pharmacy market. A monopoly was replaced by a competitive system, where five pharmacy chains now share most of the market, a competition that has made community pharmacy very commercialized. A number of different, promising primary care services are being offered, but they are usually delivered on a small scale due to a lack of remuneration and philosophy of providers. Priority is given to sales and fast dispensing of prescriptions, often with a minimum of counseling. Reflecting primary health care, community pharmacy in Sweden is at a crossroads but currently has a golden opportunity to choose a route of collaboration with primary health care in its current transformation into more local and digi-physical care. A major challenge is that primary health care inquires, strategic plans, and national policy documents usually do not include community pharmacy as a partner. Hence, community pharmacy have to be proactive and seize this chance of changes in primary health policy and organization in order to become an important link in the chain of health care delivery, or there is a significant risk that it will predominantly remain a retail business.
11
Tan, Ting Wan, Han Ling Tan, Man Na Chang, Wen Shu Lin, and Chih Ming Chang. "Effectiveness of Epidemic Preventive Policies and Hospital Strategies in Combating COVID-19 Outbreak in Taiwan." International Journal of Environmental Research and Public Health 18, no. 7 (March 26, 2021): 3456. http://dx.doi.org/10.3390/ijerph18073456.
Full textAbstract:
(1) Background: The implementation of effective control measures in a timely fashion is crucial to control the epidemic outbreak of COVID-19. In this study, we aimed to analyze the control measures implemented during the COVID-19 outbreak, as well as evaluating the responses and outcomes at different phases for epidemic control in Taiwan. (2) Methods: This case study reviewed responses to COVID-19 and the effectiveness of a range of control measures implemented for epidemic control in Taiwan and assessed all laboratory-confirmed cases between 11 January until 20 December 2020, inclusive of these dates. The confirmation of COVID-19 infection was defined as the positive result of a reverse-transcriptase–polymerase-chain-reaction test taken from a nasopharyngeal swab. Test results were reported by the Taiwan Centers for Disease Control. The incidence rate, mortality rate, and testing rate were compiled, and the risk ratio was provided to gain insights into the effectiveness of prevention measures. (3) Results and Discussion: This study presents retrospective data on the COVID-19 incidence rate in Taiwan, combined with the vital preventive control measures, in a timeline of the early stage of the epidemic that occurred in Taiwan. The implementation of multiple strategy control measures and the assistance of technologies to control the COVID-19 epidemic in Taiwan led to a relatively slower trend in the outbreak compared to the neighboring countries. In Taiwan, 766 confirmed patients were included, comprised of 88.1% imported cases and 7.2% local transmission cases, within the studied period. The incidence rate of COVID-19 in Taiwan during the studied period was 32 per million people, with a mortality rate of 0.3 per million people. Our analysis showed a significantly raised incidence risk ratio in the countries of interest in comparison to Taiwan during the study period; in the range of 1.9 to 947.5. The outbreak was brought under control through epidemic policies and hospital strategies implemented by the Taiwan Government. (4) Conclusion: Taiwan’s preventive strategies resulted in a drastically lower risk for Taiwan nationals of contracting COVID-19 when new pharmaceutical drug or vaccines were not yet available. The preventive strategies employed by Taiwan could serve as a guide and reference for future epidemic control strategies.
12
Stolar, Michael H. "National survey of hospital pharmaceutical services—1985." American Journal of Health-System Pharmacy 42, no. 12 (December 1, 1985): 2667–78. http://dx.doi.org/10.1093/ajhp/42.12.2667.
Full text
13
Stolar, Michael H. "ASHP National Survey of Hospital Pharmaceutical Services—1987." American Journal of Health-System Pharmacy 45, no. 4 (April 1, 1988): 801–18. http://dx.doi.org/10.1093/ajhp/45.4.801.
Full text
14
Crawford, Stephanie Y. "ASHP national survey of hospital-based pharmaceutical services—1990." American Journal of Health-System Pharmacy 47, no. 12 (December 1, 1990): 2665–95. http://dx.doi.org/10.1093/ajhp/47.12.2665.
Full text
15
Crawford, Stephanie Y., and Charles E. Myers. "ASHP National Survey of Hospital-based Pharmaceutical Services-1992." American Journal of Health-System Pharmacy 50, no. 7 (July 1, 1993): 1371–404. http://dx.doi.org/10.1093/ajhp/50.7.1371.
Full text
16
Santell, John P. "ASHP national survey of hospital-based pharmaceutical services—1994." American Journal of Health-System Pharmacy 52, no. 11 (June 1, 1995): 1179–96. http://dx.doi.org/10.1093/ajhp/52.11.1179.
Full text
17
Utomo, Bedjo, I. Dewa Gede Hariwisana, and Shubhrojit Misra. "Design a Low-Cost Digital Pressure Meter Equipped with Temperature and Humidity Parameters." Indonesian Journal of electronics, electromedical engineering, and medical informatics 3, no. 2 (May 28, 2021): 59–64. http://dx.doi.org/10.35882/ijeeemi.v3i2.4.
Full textAbstract:
Calibration is a technical activity which consists of determining one or more properties and characteristics of a product, process or service according to a predetermined special procedure. The purpose of calibration is to ensure measurement results comply with national and international standards. The purpose of this study is to design two mode digital pressure meter (DPM) device equipped with a thermo-hygrometer and pressure in which the design is completed with a selection mode to determine the positive and negative pressure (vacuum) using MPX 5050GP sensor as a positive pressure sensor. In this design DHT 22 sensors is used to measure the humidity and temperature. To test the leak test this device is also equipped with timer. This design uses a 2.4 inch Nextion TFT LCD screen to display data. Data analysis was performed by comparing modul with standard tools. In the measurement process, Mercury tensimeter was carried out 6 times the data and the smallest results were 0 mmHg on the module and 0 mmHg on the standard tool and the largest was 298.0 mmHg on the module and 300 mmHg on the standard tool. Data were collected in a room with a temperature of 31̊C and humidity of 87%. Finally, this design is applicable for daily used for electromedical engineer to calibrate the sphygmomanometer in the hospitals
18
YAMAZAKI, Naoya. "Therapeutic strategy for angiosarcoma in the National Cancer Center Hospital." Skin Cancer 24, no. 3 (2009): 385–91. http://dx.doi.org/10.5227/skincancer.24.385.
Full text
19
Thomas, Joseph. "National survey of hospital policies on pharmaceutical sales representatives' activities." American Journal of Health-System Pharmacy 44, no. 6 (June 1, 1987): 1334–40. http://dx.doi.org/10.1093/ajhp/44.6.1334.
Full text
20
Cho, Hae-Wol, and Chaeshin Chu. "What Would Be a Better Strategy for National University Hospital Management?" Osong Public Health and Research Perspectives 7, no. 3 (June 2016): 139–40. http://dx.doi.org/10.1016/j.phrp.2016.05.003.
Full text
21
Levi, Leon, Moshe Michaelson, Hanna Admi, David Bregman, and Ronen Bar-Nahor. "National Strategy for Mass Casualty Situations and its Effects on the Hospital." Prehospital and Disaster Medicine 17, no. 1 (March 2002): 12–16. http://dx.doi.org/10.1017/s1049023x00000054.
Full textAbstract:
AbstractA mass-casualty situation (MCS) usually is short in duration and resolves itself. To minimize the risks to patients during MCS, planning is essential. This article summarizes the preparations needed at the hospital level, for a local MCS involving numerous trauma victims arriving to the Emergency Department at a short notice. Experiences and conclusions related to the implementation of the Israeli strategy in one hospital that combines the responsibilities of both the military and civilians are summarized.The Ministry of Health distributes the master MCS plan to each hospital where a local committee adapts it to the specific situation in a format of standing orders. After its approval by the Ministry of Health, an annual inspection is conducted to check the ability of the staff to manage a MCS. A full-scale drill is conducted every second year during which each site's readiness level and the continuity of the flow of care are tested.In building the strategy for treating trauma victims during a MCS, a few assumptions were taken into account. The goal of treatment in a MCS is to deliver an acceptable quality of care while preserving as many lives as is possible. In theory, the capacity of the hospital is its ability to manage a load of patients in the range of 20% of the hospital bed capacity. Planning and drilling are the ways to minimize deviations from the guidelines and to avoid management mistakes. Special attention should be paid to problems related to the initial phase of receiving the first message, outside communication, inside hospital communication, and staff recruitment. Other issues include: free access to the hospital; opening a public information center; and dealing with the media and very important persons (VIPs).A new method for creating the needed MCS plan in the hospital is suggested. It is based upon knowledge of management techniques that used multi-level documents, which are spread via Intranet between the different key figures. Using this method, it is possible to keep the strategy, the source documentation, and reasons for choosing it, as well as immediate release of checklists for each functions. This detailed, time consuming work is worthwhile in the long run, when the benefits of easy updating and better preparedness are apparent.
22
Lima, Lívia Falcão, Bruna Cristina Cardoso Martins, Francisco Roberto Pereira de Oliveira, Rafaela Michele de Andrade Cavalcante, Vanessa Pinto Magalhães, Paulo Yuri Milen Firmino, Liana Silveira Adriano, Adriano Monteiro da Silva, Maria Jose Nascimento Flor, and Eugenie Desirée Rabelo Néri. "Pharmaceutical orientation at hospital discharge of transplant patients: strategy for patient safety." Einstein (São Paulo) 14, no. 3 (September 2016): 359–65. http://dx.doi.org/10.1590/s1679-45082016ao3481.
Full textAbstract:
ABSTRACT Objective: To describe and analyze the pharmaceutical orientation given at hospital discharge of transplant patients. Methods: This was a cross-sectional, descriptive and retrospective study that used records of orientation given by the clinical pharmacist in the inpatients unit of the Kidney and Liver Transplant Department, at Hospital Universitário Walter Cantídio, in the city of Fortaleza (CE), Brazil, from January to July, 2014. The following variables recorded at the Clinical Pharmacy Database were analyzed according to their significance and clinical outcomes: pharmaceutical orientation at hospital discharge, drug-related problems and negative outcomes associated with medication, and pharmaceutical interventions performed. Results: The first post-transplant hospital discharge involved the entire multidisciplinary team and the pharmacist was responsible for orienting about drug therapy. The mean hospital discharges/month with pharmaceutical orientation during the study period was 10.6±1.3, totaling 74 orientations. The prescribed drug therapy had a mean of 9.1±2.7 medications per patient. Fifty-nine drug-related problems were identified, in which 67.8% were related to non-prescription of medication needed, resulting in 89.8% of risk of negative outcomes associated with medications due to untreated health problems. The request for inclusion of drugs (66.1%) was the main intervention, and 49.2% of the medications had some action in the digestive tract or metabolism. All interventions were classified as appropriate, and 86.4% of them we able to prevent negative outcomes. Conclusion: Upon discharge of a transplanted patient, the orientation given by the clinical pharmacist together with the multidisciplinary team is important to avoid negative outcomes associated with drug therapy, assuring medication reconciliation and patient safety.
23
Lynas, Kathie. "Need to Revive National Strategy for Prescription Drugs Health Council of Canada." Canadian Pharmacists Journal / Revue des Pharmaciens du Canada 142, no. 2 (March 2009): 56–57. http://dx.doi.org/10.3821/1913-701x-142.2.56.
Full text
24
Ching Gu, Vicky, and James R. Burns. "The launch strategy choices in China’s pharmaceutical market." International Journal of Pharmaceutical and Healthcare Marketing 10, no. 3 (September 5, 2016): 339–56. http://dx.doi.org/10.1108/ijphm-06-2015-0030.
Full textAbstract:
Purpose This paper aims to study the drug launch strategies and their effects on new drug performance in an intensely competitive emerging pharmaceutical market such as the one in China. Design/methodology/approach Data on market share, sales, related firm size and annual profit were obtained for the period, 2004-2008. Profile deviation and cluster analysis approaches were applied in this study. Findings There is a significant effect of an optimal launch strategy on new drug performance given the respective resource availability and the market environment situations. Practical implications The study suggests that multi-national corporations may prove resilient in the emerging economies through both innovative and cost-driven offerings in different therapeutic categories. Originality/value This research is unique in studying the drug launch strategies across both foreign firms and local firms in a competitive emerging pharmaceutical market.
25
Allers, Eugene, U. A. Botha, O. A. Betancourt, B. Chiliza, Helen Clark, J. Dill, Robin Emsley, et al. "The 15th Biannual National Congress of the South African Society of Psychiatrists, 10-14 August 2008, Fancourt, George, W Cape." South African Journal of Psychiatry 14, no. 3 (August 1, 2008): 18. http://dx.doi.org/10.4102/sajpsychiatry.v14i3.165.
Full textAbstract:
<p><strong>1. How can we maintain a sustainable private practice in the current political and economic climate?</strong></p><p>Eugene Allers</p><p><strong>2. SASOP Clinical guidelines, protocols and algorithms: Development of treatment guidelines for bipolar mood disorder and major depression</strong></p><p> Eugene Allers, Margaret Nair, Gerhard Grobler</p><p><strong>3. The revolving door phenomenon in psychiatry: Comparing low-frequency and high-frequency users of psychiatric inpatient services in a developing country</strong></p><p>U A Botha, P Oosthuien, L Koen, J A Joska, J Parker, N Horn</p><p><strong>4. Neurophysiology of emotion and senses - The interface between psyche and soma</strong></p><p>Eugene Allers</p><p><strong>5. Suicide prevention: From and beyond the psychiatrist's hands</strong></p><p>O Alonso Betanourt, M Morales Herrera</p><p><strong>6. Treatment of first-episod psychosis: Efficacy and toleabilty of a long-acting typical antipsychotic </strong></p><p>B Chiliza, R Schoeman, R Emsey, P Oosthuizen, L KOen, D Niehaus, S Hawkridge</p><p><strong>7. Treatment of attention deficit hyperactivity disorder in the young child</strong></p><p>Helen Clark</p><p><strong>8. Holistic/ Alternative treatment in psychiatry: The value of indigenous knowledge systems in cllaboration with moral, ethical and religious approaches in the military services</strong></p><p>J Dill</p><p><strong>9. Treating Schizophrenia: Have we got it wrong?</strong></p><p>Robin Emsley</p><p><strong>10.Terminal questions in the elderly</strong></p><p>Mike Ewart Smith</p><p><strong>11. Mental Health Policy development and implementation in Ghana, South Africa, Uganda and Zambia</strong></p><p>Alan J Flisher, Crick Lund, Michelle Frank, Arvin Bhana, Victor Doku, Natalie Drew, Fred N Kigozi, Martin Knapp, Mayeh Omar, Inge Petersen, Andrew Green andthe MHaPP Research Programme Consortium</p><p><strong>12. What indicators should be used to monitor progress in scaling uo services for people with mental disorders?</strong></p><p>Lancet Global Mental Health Group (Alan J Flisher, Dan Chisholm, Crick Lund, Vikram Patel, Shokhar Saxena, Graham Thornicroft, Mark Tomlinson)</p><p><strong>13. Does unipolar mania merit research in South Africa? A look at the literature</strong></p><p>Christoffel Grobler</p><p><strong>14. Revisiting the Cartesian duality of mind and body</strong></p><p>Oye Gureje</p><p><strong>15. Child and adolescent psychopharmacology: Current trends and complexities</strong></p><p>S M Hawkridge</p><p><strong>16. Integrating mental illness, suicide and religion</strong></p><p>Volker Hitzeroth</p><p><strong>17. Cost of acute inpatient mental health care in a 72-hour assessment uniy</strong></p><p>A B R Janse van Rensburg, W Jassat</p><p><strong>18. Management of Schizophrenia according to South African standard treatment guidelines</strong></p><p>A B R Janse van Rensburg</p><p><strong>19. Structural brain imaging in the clinical management of psychiatric illness</strong></p><p>F Y Jeenah</p><p><strong>20. ADHD: Change in symptoms from child to adulthood</strong></p><p>S A Jeeva, A Turgay</p><p><strong>21. HIV-Positive psychiatric patients in antiretrovirals</strong></p><p>G Jonsson, F Y Jeenah, M Y H Moosa</p><p><strong>22. A one year review of patients admitted to tertiary HIV/Neuropsychiatry beds in the Western Cape</strong></p><p>John Joska, Paul Carey, Ian Lewis, Paul Magni, Don Wilson, Dan J Stein</p><p><strong>23. Star'd - Critical review and treatment implications</strong></p><p>Andre Joubert</p><p><strong>24. Options for treatment-resistent depression: Lessons from Star'd; an interactive session</strong></p><p>Andre Joubert</p><p><strong>25. My brain made me do it: How Neuroscience may change the insanity defence</strong></p><p>Sean Kaliski</p><p><strong>26. Child andadolescent mental health services in four African countries</strong></p><p>Sharon Kleintjies, Alan Flisher, Victoruia Campbell-Hall, Arvin Bhana, Phillippa Bird, Victor Doku, Natalie, Drew, Michelle Funk, Andrew Green, Fred Kigozi, Crick Lund, Angela Ofori-Atta, Mayeh Omar, Inge Petersen, Mental Health and Poverty Research Programme Consortium</p><p><strong>27. Individualistic theories of risk behaviour</strong></p><p>Liezl Kramer, Volker Hitzeroth</p><p><strong>28. Development and implementation of mental health poliy and law in South Africa: What is the impact of stigma?</strong></p><p>Ritsuko Kakuma, Sharon Kleintjes, Crick Lund, Alan J Flisher, Paula Goering, MHaPP Research Programme Consortium</p><p><strong>29. Factors contributing to community reintegration of long-term mental health crae users of Weskoppies Hospital</strong></p><p>Carri Lewis, Christa Kruger</p><p><strong>30. Mental health and poverty: A systematic review of the research in low- and middle-income countries</strong></p><p>Crick Lund, Allison Breen, Allan J Flisher, Ritsuko Kakuma, Leslie Swartz, John Joska, Joanne Corrigall, Vikram Patel, MHaPP Research Programe Consortium</p><p><strong>31. The cost of scaling up mental health care in low- and middle-income countries</strong></p><p>Crick Lund, Dan Chishlom, Shekhar Saxena</p><p><strong>32. 'Tikking'Clock: The impact of a methamphetamine epidemic at a psychiatric hospital in the Western Cape</strong></p><p>P Milligan, J S Parker</p><p><strong>33. Durban youth healh-sk behaviour: Prevalence f Violence-related behaviour</strong></p><p>D L Mkize</p><p><strong>34. Profile of morality of patients amitted Weskoppies Psychiatric Hospital in Sout frican over a 5-Year period (2001-2005)</strong></p><p>N M Moola, N Khamker, J L Roos, P Rheeder</p><p><strong>35. One flew over Psychiatry nest</strong></p><p>Leverne Mountany</p><p><strong>36. The ethical relationship betwe psychiatrists and the pharmaceutical indutry</strong></p><p>Margaret G Nair</p><p><strong>37. Developing the frameor of a postgraduate da programme in mental health</strong></p><p>R J Nichol, B de Klerk, M M Nel, G van Zyl, J Hay</p><p><strong>38. An unfolding story: The experience with HIV-ve patients at a Psychiatric Hospital</strong></p><p>J S Parker, P Milligan</p><p><strong>39. Task shifting: A practical strategy for scalingup mental health care in developing countries</strong></p><p>Vikram Patel</p><p><strong>40. Ethics: Informed consent and competency in the elderly</strong></p><p>Willie Pienaar</p><p><strong>41. Confronting ommonmoral dilemmas. Celebrating uncertainty, while in search patient good</strong></p><p>Willie Pienaar</p><p><strong>42. Moral dilemmas in the treatment and repatriation of patients with psychtorders while visiting our country</strong></p><p>Duncan Ian Rodseth</p><p><strong>43. Geriatrics workshop (Psegal symposium): Medico-legal issuess in geriatric psyhiatry</strong></p><p>Felix Potocnik</p><p><strong>44. Brain stimulation techniques - update on recent research</strong></p><p>P J Pretorius</p><p><strong>45. Holistic/Alternative treatments in psychiatry</strong></p><p>T Rangaka, J Dill</p><p><strong>46. Cognitive behaviour therapy and other brief interventions for management of substances</strong></p><p>Solomon Rataemane</p><p><strong>47. A Transtheoretical view of change</strong></p><p>Nathan P Rogerson</p><p><strong>48. Profile of security breaches in longerm mental health care users at Weskoppies Hospital over a 6-month period</strong></p><p>Deleyn Rema, Lindiwe Mthethwa, Christa Kruger</p><p><strong>49. Management of psychogenic and chronic pain - A novel approach</strong></p><p>M S Salduker</p><p><strong>50. Childhood ADHD and bipolar mood disorders: Differences and similarities</strong></p><p>L Scribante</p><p><strong>51. The choice of antipsychotic in HIV-infected patients and psychopharmacocal responses to antipsychotic medication</strong></p><p>Dinesh Singh, Karl Goodkin</p><p><strong>52. Pearls in clinical neuroscience: A teaching column in CNS Spectrums</strong></p><p><strong></strong>Dan J Stein</p><p><strong>53. Urinary Cortisol secretion and traumatics in a cohort of SA Metro policemen A longitudinal study</strong></p><p>Ugash Subramaney</p><p><strong>54. Canabis use in Psychiatric inpatients</strong></p><p><strong></strong>M Talatala, G M Nair, D L Mkize</p><p><strong>55. Pathways to care and treatmt in first and multi-episodepsychosis: Findings fm a developing country</strong></p><p>H S Teh, P P Oosthuizen</p><p><strong>56. Mental disorders in HIV-infected indivat various HIV Treatment sites in South Africa</strong></p><p>Rita Thom</p><p><strong>57. Attendanc ile of long-term mental health care users at ocupational therapy group sessions at Weskoppies Hospital</strong></p><p>Ronel van der Westhuizen, Christa Kruger</p><p><strong>58. Epidemiological patterns of extra-medical drug use in South Africa: Results from the South African stress and health study</strong></p><p>Margaretha S van Heerden, Anna Grimsrud, David Williams, Dan Stein</p><p><strong>59. Persocentred diagnosis: Where d ps and mental disorders fit in the International classificaton of diseases (ICD)?</strong></p><p>Werdie van Staden</p><p><strong>60. What every psychiatrist needs to know about scans</strong></p><p>Herman van Vuuren</p><p><strong>61. Psychiatric morbidity in health care workers withle drug-resistant erulosis (MDR-TB) A case series</strong></p><p>Urvashi Vasant, Dinesh Singh</p><p><strong>62. Association between uetrine artery pulsatility index and antenatal maternal psychological stress</strong></p><p>Bavanisha Vythilingum, Lut Geerts, Annerine Roos, Sheila Faure, Dan J Stein</p><p><strong>63. Approaching the dual diagnosis dilemma</strong></p><p>Lize Weich</p><p><strong>64. Women's mental health: Onset of mood disturbance in midlife - Fact or fiction</strong></p><p>Denise White</p><p><strong>65. Failing or faking: Isses in the fiagnosis and treatment of adult ADHD</strong></p><p>Dora Wynchank</p>
26
Lee, Munjae. "Competitive Strategy for Successful National University Hospital Management in the Republic of Korea." Osong Public Health and Research Perspectives 7, no. 3 (June 2016): 149–56. http://dx.doi.org/10.1016/j.phrp.2016.02.002.
Full text
27
Tsui, Charlotte, Rachel Klein, and Matthew Garabrant. "Minimally invasive surgery: national trends in adoption and future directions for hospital strategy." Surgical Endoscopy 27, no. 7 (May 10, 2013): 2253–57. http://dx.doi.org/10.1007/s00464-013-2973-9.
Full text
28
Thomas, Joseph. "National survey of recent changes in hospital policies on pharmaceutical sales representatives' activities." American Journal of Health-System Pharmacy 46, no. 3 (March 1, 1989): 565–69. http://dx.doi.org/10.1093/ajhp/46.3.565.
Full text
29
Morgan, Steven, Marc-André Gagnon, Barbara Mintzes, and Joel Lexchin. "A Better Prescription: Advice for a National Strategy on Pharmaceutical Policy in Canada." Healthcare Policy | Politiques de Santé 12, no. 1 (August 22, 2016): 18–36. http://dx.doi.org/10.12927/hcpol.2016.24637.
Full text
30
Reid, TD, LJ Finney, and AR Hedges. "The National Stroke Strategy – Is it Achievable?" Annals of The Royal College of Surgeons of England 91, no. 8 (November 2009): 641–44. http://dx.doi.org/10.1308/003588409x432491.
Full textAbstract:
INTRODUCTION Timing of intervention in symptomatic carotid disease is critical. The UK Department of Health's National Stroke Strategy published in December 2007 recommends urgent carotid intervention within 48 h, in appropriate patients, who have suffered a transient ischaemic attack (TIA), amaurosis fugax or minor stroke. Despite the running of a rapid-access clinic for patients with symptoms of TIA, the time from symptom to surgery is rarely less than 2 weeks. To date, there has been little published research on the UK public response to the symptoms of TIA, and no study at all of the response of primary care to such patients. The aim of this study was to ascertain both these responses to see whether a 48-h target is achievable. PATIENTS AND METHODS A total of 402 men attending our aortic aneurysm screening sessions were asked to complete a questionnaire requesting their most likely response to an episode of amaurosis fugax or TIA. All 45 GP practices in the hospital catchment area were asked how they would respond to patients requesting to be seen with the symptoms used in the questionnaire. RESULTS Nearly one in six patients would ignore the symptom unless it recurred, approximately half would request a GP appointment and a third would see an optician if they had amaurosis fugax. The mean waiting time to see a GP was 2 days for a routine appointment and within 24 h for an emergency appointment. CONCLUSIONS It is clear that a significant number of people would ignore the first symptom of carotid ischaemia; for those with amaurosis fugax, nearly a third would initially seek help from their optician. Those given a routine GP appointment would have to wait a minimum of 2 days. If the Department of Health is serious about reducing the incidence of stroke and introducing a target of 48 h from symptom to treatment, then there needs to be a wide-spread public and healthcare education programme, in particular alerting opticians and GP receptionists that these symptoms constitute a medical emergency.
31
Diah Tirta Kosala, Ida Ayu, and Agus Fredy Maradona. "Can Government Hospital Survive in The Era of National Health Insurance?" Jurnal Manajemen Bisnis 16, no. 2 (April 17, 2019): 50. http://dx.doi.org/10.38043/jmb.v16i2.2040.
Full textAbstract:
ABSTRACT Based on the Minister of Health Regulation Number 28 of 2014 concerning the National Health Insurance Program Implementation Program which is needed to fulfill the basic needs of every person who has to pay contributions or contributions that are approved by the government. Health is a basic human need to be able to live a decent and productive life, for this reason it is necessary to carry out quality-controlled health care and costs, through the National Health Insurance (JKN) program organized by the Social Security Organizing Agency (BPJS). Hospitals are needed to implement business strategies with display-based resources in order to be able to compete in a tiered, competency-based referral system. This research was conducted at the Tabanan Regency BRSUD with the aim of finding out the business strategy and efforts made by government hospitals in improving excellent service in the JKN era. This study uses qualitative research with a case study approach. Data collection by interview and documentation study. The sampling technique with purposive sampling, Credibility Test (internal validity) using source triangulation techniques. From the results of the study it can be concluded that the applied business strategy is to improve core competencies (core competency) and hospital capabilities, innovating in all forms of service support and efforts to support excellent service are improving quality, efficiency and financial supply chain to achieve sustainable competitive advantage.
32
Kohl, Stephanie. "Putting the patient at the centre – Pharmaceutical Strategy for Europe welcomed by hospital pharmacists." European Journal of Hospital Pharmacy 28, no. 1 (December 18, 2020): 54–56. http://dx.doi.org/10.1136/ejhpharm-2020-002629.
Full text
33
Aminah, Nenden Siti, Ratna Djuwita, Paulus Daniel Sahanggamu, Soelistyo Soelistyo, and Helmi Suryani Nasution. "Active Surveillance: Strategy to Reach The Unreported TB Patient In Hospitals." Syntax Literate ; Jurnal Ilmiah Indonesia 6, no. 7 (July 19, 2021): 3417. http://dx.doi.org/10.36418/syntax-literate.v6i7.3465.
Full textAbstract:
Background and Aims: The National Tuberculosis Program (NTP) conducted active surveillance to find unreported TB patients in hospitals. CTB supports by conducted active surveillance in 6 provinces. This study was conducted to see an overview of the implementation of active surveillance of TB cases in hospitals among districts supported by CTB and non CTB supported, including the challenges of active surveillance implementation to provide recommendations for National TB program. Methods: This study is a qualitative research with a case study design. Data collected by document reviews, observations, discussions, and in-depth interviews with key informants. Results: Only about 23% of TB cases from HIS are reported into SITT. This is partly due to the procedure or the flow of tuberculosis (TB) data from the Hospital to the National TB Program, which is a manuallly input by entry the data into the SITT.There are about 70% of cases that are not reportedly due to lack of human resources in the hospital to do data entry. Findings also show that districts supported by CTB have a percentage of cases gap less (4%-43%) than non CTB supported district (43%-74%). The data shows the importance of partnership or involvement of other partners in TB control programs. Conclusion: Active surveillance shows the need to strengthen hospital internal network. Standardized guideline and treatment monitoring mechanism should be established to support active surveillance nationwide. The NTP needs also to collaborate with the Directorate General of Health Services to establish a linkage between HIS and National TB surveillance system.
34
Klunko, Natalia S. "CONCEPTUAL APPROACH TO THE NATIONAL PHARMACEUTICAL COMPLEX DEVELOPMENT BASED ON AN ADAPTIVE MANAGEMENT APPROACH." Scientific Review. Series 1. Economics and Law, no. 5 (2020): 52–69. http://dx.doi.org/10.26653/2076-4650-2020-5-05.
Full textAbstract:
Conceptual principles of the national pharmaceutical complex development based on an adaptive management approach are considered in the article. The essence of adaptive management is determined to be a complex structured process able to be implemented both at the expense of existing current assets and attracted resources which can be redistributed between management subjects through an appropriate management strategy. The directions of development and implementation of the development strategy for the pharmaceutical complex are analyzed herein. Possibilities are investigated how to ensure its innovative and dynamic development through elaboration of all functional subsystems of management.
35
Turchet, Cassandra, Amanda B. Canfield, David Williamson, Chris Fan-Lun, Najla Tabbara, Ioanna Mantas, Samir Sinha, and Lisa Burry. "Detecting Delirium in Hospitalized Elderly Patients: A Review of Practice Compliance." Journal of Pharmacy Technology 34, no. 3 (February 2, 2018): 91–98. http://dx.doi.org/10.1177/8755122518756331.
Full textAbstract:
Background: The Ontario Senior Friendly Hospital Strategy recognizes delirium prevention and management as a top priority and recommends implementation of delirium screening as well as management protocols. This strategy proposes that hospitals monitor 2 specific indicators: (1) rate of baseline delirium screening and (2) rate of hospital-acquired delirium. Objective: To (1) determine compliance with the Ontario Senior Friendly Hospital Strategy indicators; (2) describe the use of pharmacological and nonpharmacological interventions for management of delirious patients; and (3) identify predictors of screening compliance. Methods: We conducted a retrospective review of patients aged ≥65 years admitted to 4 different inpatient units for ≥48 hours. Data were extracted for 7 two-month time blocks chosen between September 2010 and October 2013, following the implementation of various geriatric and delirium related initiatives at the hospital. Results: A total of 786 patients met study inclusion criteria. Overall, 68.2% had baseline delirium screening (indicator 1), with screening rates increasing over time ( P < .001). Inpatient unit and year of study were both statistically significant predictors of delirium screening. Among those screened, the overall rate of hospital-acquired delirium was 17.2% (indicator 2). Early mobilization and device removal were the most common nonpharmacological interventions, while initiation of an antipsychotic and discontinuation of benzodiazepines were the most common pharmacological interventions. Conclusions: Although the rates of baseline delirium screening have significantly increased over the sampled time period, rates are still below the averages referenced in other literature. Our study suggests we need additional efforts to improve compliance with delirium screening in our institution.
36
Lynas, Kathie. "Pharmacists can play a key role in implementing new national strategy to combat prescription drug abuse." Canadian Pharmacists Journal / Revue des Pharmaciens du Canada 146, no. 3 (May 2013): 128–29. http://dx.doi.org/10.1177/1715163513488322.
Full text
37
Nugraheni, Wahyu Pudji, Asri Hikmatuz Zahroh, and Risky Kusuma Hartono. "BEST PRACTICE OF HOSPITAL MANAGEMENT STRATEGY TO THRIVE IN THE NATIONAL HEALTH INSURANCE (JKN) ERA." Jurnal Administrasi Kesehatan Indonesia 9, no. 1 (June 7, 2021): 9. http://dx.doi.org/10.20473/jaki.v9i1.2021.9-22.
Full textAbstract:
Background: The implementation of the National Health Insurance (JKN) program has created a transformation in the health care system in Indonesia. Many hospitals were stuttering and unable to adapt to the new payment system. Some hospitals complained about INA-CBG rates that were lower than the real rates, so that hospitals suffered losses.Aims: This research aims to take the best practice from one government hospital and one private hospital that is able to thrive in the JKN era.Methods: This study used qualitative research methods through in-depth interviews.Results: The similarity of strategies carried out by the two best practice hospitals to thrive in JKN era are efficiency in business process, investment in human resources, customer relationship management, and stakeholders collaboration.Conclusion: The results of this study can be used as a reference for government and private hospitals in Indonesia to be able to thrive in the JKN era.Keywords: best practice, hospital, National Health Insurance, strategy
38
Rahman, Md H., Rokeya Akter, Tapan Behl, Md A. R. Chowdhury, Manirujjaman Mohammed, Israt J. Bulbul, Shimaa E. Elshenawy, and Mohammad A. Kamal. "COVID-19 Outbreak and Emerging Management through Pharmaceutical Therapeutic Strategy." Current Pharmaceutical Design 26, no. 41 (December 12, 2020): 5224–40. http://dx.doi.org/10.2174/1381612826666200713174140.
Full textAbstract:
The latest SARS COV2 coronavirus contributes to a pandemic of millions of COVID-19. As there is no defensive immunity in humans and a virus can overcome inborn immune reaction, it can propagate unhindered, mostly in tissues contaminated. No unique therapies for COVID-19 contaminated patients are available at this time. The insights learned from previous respiratory viral infection control have given guidance into COVID- 19 therapy. Several complementary treatments have been tentatively introduced in hospital environments such as immune-modulators, antiviral, convalescent plasma transfusions and natural products. In COVID-19 patients, some of these therapies have provided substantial curative benefits. Moreover, numerous studies and clinical trials are being carried out in order to determine the efficacy of current pharmaceutical and natural products to establish possible therapeutic strategies for producing novel COVID-19 medicines. We summarized and defined the modes of mechanism, protection and efficacy on the existing therapeutic strategies for diseases linked to COVID-19 infection.
39
Ocio, Enrique M., Laura Rosinol, Marta Grande, Ana Ruiz-Zorrilla, Alonso Fernandez, and Carmen Montoto. "Socio-Demographic Features and Societal Perspective of Relapse and/or Refractory Multiple Myeloma (RRMM) Patients in Spain: An Interim Analysis of Charismma Study." Blood 132, Supplement 1 (November 29, 2018): 2300. http://dx.doi.org/10.1182/blood-2018-99-114430.
Full textAbstract:
Abstract Introduction Multiple myeloma (MM) is a plasma cell malignancy, with a range of clinical features including hypercalcaemia, renal insuficiency, anaemia and bone lesions1 (CRAB). MM progression often involves multiple rounds of remissions after treatment followed by subsequent relapses2. Although MM accounts for only a small percentage of all cancer types, the costs associated with treating and managing it are among the highest3. RRMM population is heterogeneous, their characteristics depend on the number and type of treatment used, and the type of relapse3. Selection of treatment for MM patients is challenging due to increased age and the often associated comorbid conditions4. RRMM patients are more symptomatic, vulnerable to adverse events and, more likely to incur a dose reduction or early discontinuation of therapy. Balancing expected efficacy of therapy vs potential toxicities, health care resources and impact on patients' Health Related Quality of Life (HRQOL) is therefore critical in this patient population5. CharisMMa study objective (NCT03188536) is to understand and provide an accurate epidemiological and societal characterization of RRMM patients. Hematologist's choice of therapeutic strategy is crucial, and must be made in consideration of the patient as a whole, and not only in terms of their disease. Methods CharisMMa is an observational, cross-sectional, multicentre study, involving 30 public hospitals around Spain, which include MM patients that require treatment at any relapse of the disease. An interim analysis has been conducted evaluating socio-demographic characteristics and burden of the disease in the 169 patients with relapse/refractory MM enrolled up to June 2018 (expected n=350). On average, information was collected 2.15 (SD: 1.76) months after the last relapse. Results The median age in the moment of the study visit, was 69.0 (57.0, 75.0) years, being 55.2% male. 71.8% of them lived in urban areas and 88% with their families. Most of them were retired (64.2%) and non-dependent (73.1%). Patients included have been treated with a median of 2.0 (1.0, 3.0) previous lines. Approximately half of them (56.7%) had received stem cell transplant (97.8% autologous). The stage ISS was I (36.3%), II (35.6%) and III (28.1%) and 74.0% presented CRAB symptoms, being bone lesions (65.6%) the most frequent ones. 85.4% were considered intermediate or high risk patients presenting extramedullary plasmocytomas in 16.5% of the cases. 67.5% of the patients suffered from any comorbidity, being the most frequent one cardiovascular (48.1%), diabetes (23.1%) and neuropathy (22.1%). Symptomatic patients are treated mainly with doublets both in second (59.7%) and third/+ lines while those asymptomatic ones with no CRAB symptoms at relapse are treated with doublets in second but with monotherapy (62.5%) in third/+ lines (Table 1). In terms of societal perspective, on average, patients are living 23.9 (40.4) km far from their hospital and they attend 5.4 (5.0) times per month in order to visit the haematologist being 3.8 (2.7) times treatment related. In most of the visits (90.3%) patients attended accompanied by a caregiver who is occupationally active (57.4%). Only during the last relapse patients have been admitted 1.5 (1.0) times to the hospital having spent 15.2 (15.5) days until discharge. The patients are also visiting other specialist during the last relapse due to the disease as primary health care professionals (21.3%), psychologists (4.7%) and others (33.1%). Conclusions The heterogeneity in the MM patient´s characteristics is a major factor that should be considered during the management and the evolution of the disease and it has a direct impact in the resources needed. An individual approach including patients and disease characteristics should be considered in order to maximize clinical outcomes and guarantee an appropriate use of the resources in order to maximize patient´s benefit and reduce indirect costs of the disease. References Palumbo, K. Anderson. N. Engl. J. Med. 364 (2011)1046-1060. National Cancer Institute. SEER Program. Cancer stat facts: myeloma. 2016. Available at https://seer.cancer.gov/statfacts/html/mulmy.html Laubach J et al. Leukemia 2016; 30(5):1005-1017. Sonneveld P, Broijl A. Haematologica 101(4):396-406. Larocca A, Palumbo A. Blood 2015; 126 (19):2179-2185. Disclosures Ocio: BMS: Consultancy; Seattle Genetics: Consultancy; AbbVie: Consultancy; Pharmamar: Consultancy; Janssen: Consultancy, Honoraria; Takeda: Consultancy, Honoraria; Novartis: Consultancy, Honoraria; Sanofi: Research Funding; Amgen: Consultancy, Honoraria, Research Funding; Mundipharma: Research Funding; Celgene: Consultancy, Honoraria, Research Funding; Array Pharmaceuticals: Research Funding. Rosinol:Janssen, Celgene, Amgen, Takeda: Honoraria. Grande:Takeda: Employment. Ruiz-Zorrilla:Takeda: Employment. Fernandez:Takeda: Employment. Montoto:Takeda: Employment.
40
Griffith, John R., Jeffrey A. Alexander, Richard C. Jelinek, and David A. Foster. "Is Anybody Managing the Store? National Trends in Hospital Performance." Journal of Healthcare Management 51, no. 6 (November 2006): 392–405. http://dx.doi.org/10.1097/00115514-200611000-00009.
Full text
41
PSAREVA, Nadezhda. "Development strategy for the pharmaceutical and medical industry: results of the implementation." Vestnik BIST (Bashkir Institute of Social Technologies) 101, no. 1(50) (March 31, 2021): 7–13. http://dx.doi.org/10.47598/2078-9025-2021-1-50-7-13.
Full textAbstract:
The strategy for the development of the pharmaceutical industry is closely linked to ensuring the national security of Russia. In connection with the situation caused by the spread of COVID-19, the development of this industry is of particular relevance. An analysis of the implementation of the pharmaceutical industry development program based on one of the indicators — the share of imported products in the commercial pharmaceutical market in the period from 2016 to 2021 shows that the Russian pharmaceutical industry will take a worthy place in the world market and will become a source of GDP growth.
42
Vargas, Emilio, Miguel Puerro, Antonio Portoles, Mar García-Arenillas, Maria I. Ambit, and Alfonso Moreno. "Use of Intravenous Omeprazole in a University Hospital." Journal of Pharmacy Technology 13, no. 1 (January 1997): 32–35. http://dx.doi.org/10.1177/875512259701300111.
Full textAbstract:
Objective: To evaluate the characteristics of using intravenous omeprazole in a university hospital. Method: A prospective follow-up of all patients (n = 108) treated with intravenous omeprazole in our hospital was done from October 1994 through May 1995. Based on requests sent to the pharmacy service, patients receiving this drug were located and their charts were reviewed. The patients were visited daily throughout the duration of their treatment to evaluate any change in dosage, addition of new drugs to the regimen, and the final date of treatment. Results: Only 52% of the patients received omeprazole for indications in which its usefulness is clearly demonstrated. The dosages used frequently exceeded those recommended by the pharmaceutical manufacturer and in the literature. In fact, more than 50% of the patients were treated with dosages over 40 mg/d. It would have been possible to administer omeprazole orally instead of intravenously in 17% of the patients. Twenty-three percent of the patients were treated simultaneously with omeprazole and histamine2-antagonists. Conclusions: The use of intravenous omeprazole in our hospital is not optimal; thus, it seems that a strategy to improve this situation should be designed.
43
Jeon, Sung Ryul, Jung Eun Ha, and Hyun Soon Sohn. "A Survey of Pharmacy Students' Perceptions of National Drug Supply Strategy through Public Pharmaceutical Companies." Korean Journal of Clinical Pharmacy 27, no. 4 (December 30, 2017): 238–49. http://dx.doi.org/10.24304/kjcp.2017.27.4.238.
Full text
44
Manson, Nick. "Telemedicine and the New Children's Hospital (Royal Alexandra Hospital for Children)." Journal of Telemedicine and Telecare 3, no. 1_suppl (June 1997): 46–48. http://dx.doi.org/10.1258/1357633971930337.
Full textAbstract:
Telemedicine is an important factor in the future strategy of the Royal Alexandra Hospital for Children. As a state, national and international centre of excellence, it is the hospital's role to assist in the development of the best child health services. An important aim is to provide easy access to a full range of paediatric services through the provision of a comprehensive telemedicine service, which encompasses videoconferencing and tele-imaging, and positions the child as the centre of service provision. Experience so far suggests that in Australia, as in other countries, the adoption of telemedicine may outstrip the ability of the legislative and administrative frameworks to keep pace. Thus, the enablers appear to be cultural and technological while the obstacles are rooted in the way in which health systems are financed and administered.
45
Anderson, Ian, Angela Clarke, Russell Renhard, Michael Otim, and Shawana Andrews. "Linking acute care to a strategy for improving Aboriginal health." Australian Health Review 25, no. 5 (2002): 118. http://dx.doi.org/10.1071/ah020118.
Full textAbstract:
In this paper we consider the extent to which strategies to improve access to acute care services have been integrated with national strategies to improve Aboriginal health outcomes. To do this we review the primary and secondary sources and provide an overview of current national strategy in Aboriginal health and identify where policy and strategic issues relevant to acute care have been developed. In particular we consider the extent to which national policy processes have focussed on the interface between the primary and acute sectors. It is our contention that nationally integrated strategies to improve access to the acute care sector require the development of an Aboriginal health focus in hospital based quality assurance processes and a comprehensive engagement with Aboriginal issues across the acute care sector.
46
Walter, Emmanuel B., Norma J. Allred, Geeta K. Swamy, Anne S. Hellkamp, and Rowena J. Dolor. "Influenza Vaccination of Household Contacts of Newborns A Hospital-Based Strategy to Increase Vaccination Rates." Infection Control & Hospital Epidemiology 31, no. 10 (October 2010): 1070–73. http://dx.doi.org/10.1086/656563.
Full textAbstract:
We implemented a hospital-based influenza vaccination program for household contacts of newborns. Among mothers not vaccinated prenatally, 44.7% were vaccinated through the program, as were 25.7% of fathers. A hospital-based program provided opportunities for vaccination of household contacts of newborns, thereby facilitating better adherence to national vaccination guidelines.
47
Shook, Lisa Marie, Christina Bennett Farrell, Karen A. Kalinyak, Stephen C. Nelson, Brandon M. Hardesty, Angeli Rampersad, Kay Linn Saving, et al. "Using Project Echo Telementoring to Improve Sickle Cell Disease Care in the Midwest." Blood 128, no. 22 (December 2, 2016): 5923. http://dx.doi.org/10.1182/blood.v128.22.5923.5923.
Full textAbstract:
Abstract Sickle Treatment and Outcomes Research in the Midwest (STORM) is a regional sickle cell network, funded by the Health Resources and Services Administration Treatment Demonstration Project (HRSA U1EMC27863), established to improve outcomes for individuals with sickle cell disease (SCD) living in Indiana, Illinois, Michigan, Minnesota, Ohio and Wisconsin. The STORM network is led by pediatric and adult hematologists who coordinate network activities in each state, along with a Regional Coordinating Center that organizes efforts throughout the Midwest. The goal of the STORM network is to increase the number of pediatric and adult primary care providers (PCP) who are knowledgeable about the management and treatment of SCD, and who are willing to prescribe and manage hydroxyurea therapy as a means to improve medical care for the approximately 15,000 individuals living with SCD in the Midwest. One PCP engagement strategy that has been implemented to increase provider knowledge in the region is replication of the Project ECHOTM (Extension for Community Healthcare Outcomes) telementoring model. Project ECHO was developed by the University of New Mexico to utilize low-cost, high-impact video technology to link expert inter-disciplinary specialist teams with primary care providers to improve management of chronic diseases. This guided practice telementoring model delivers complex specialty medical care to underserved areas, reduces health disparities, and increases workforce capacity. Project ECHO's methodology is based on 1) using telehealth technology to build healthcare resources where they are scarce; 2) sharing best practices to reduce variation in clinical care; 3) utilizing practice-based learning to develop specialty expertise among providers; and 4) monitoring and evaluating provider outcomes. Project ECHO has demonstrated improved healthcare outcomes in Hepatitis C and several other chronic diseases, and is now being piloted by STORM to test its feasibility and applicability for SCD by using a regional approach with CME accreditation. STORM network site physician leads in each state are recruiting multi-disciplinary primary care teams to participate as "spokes" in monthly SCD TeleECHO clinics. The "hub" led by the STORM Regional Coordinating Center, located at Cincinnati Children's Hospital Medical Center, coordinates implementation and evaluation of the telementoring clinics, delivered through monthly teaching sessions. STORM TeleECHO participants log onto an internet-based virtual meeting site, using a webcam to interact during the session. STORM TeleECHO clinics include brief didactic presentations from nationally-recognized SCD content experts with topics and curriculum based on the National Heart Lung and Blood Institute Evidence-Based Management of Sickle Cell Disease guidelines released in 2014. TeleECHO teaching clinics also include 1-2 de-identified, HIPAA protected case discussions (pediatric and adult) presented by providers who would like medical and psychosocial feedback on management of challenging clinical scenarios. Providers participating in the STORM TeleECHO complete an initial survey assessing knowledge and comfort levels, practice behaviors (including hydroxyurea prescribing practices) and clinic demographics. Satisfaction surveys are sent to participants after each session as part of the CME-credit evaluation. Follow-up surveys at 6 months and 1 year will assess satisfaction, knowledge, comfort level and changes in practice. STORM's TeleECHO was launched in March 2016. Preliminary data indicate an interest in STORM TeleECHO teaching sessions by both pediatric and adult providers across the Midwest region. Future efforts will expand the network to more PCPs in the region, while improving the applicability and utility of STORM TeleECHO in SCD through provider assessment. Disclosures Ware: Global Blood Therapeutics: Consultancy; Biomedomics: Research Funding; Bristol Myers Squibb: Research Funding; Addmedica: Research Funding; Nova Laboratories: Consultancy; Bayer Pharmaceuticals: Consultancy.
48
Zverev, A., O. Kuznetsova, and M. Mishina. "Formation of Strategy for Sustainable Development of Entrepreneurial Structures of Pharmaceutical Industry." Scientific Research and Development. Economics 9, no. 1 (March 1, 2021): 36–44. http://dx.doi.org/10.12737/2587-9111-2021-36-44.
Full textAbstract:
The article reflects the significance and peculiarities of the functioning of the entrepreneurial structure of the pharmaceutical industry, which are closely connected with the health system and play one of the key roles in the national economy of any state, influencing the future of the nation. The authors assessed the modern problems of the development of the domestic pharmaceutical industry, studied expert opinions on sustainable development options, and on this basis proposed a set of measures to optimize the economic development of Russian commercial pharmaceutical structures within the framework of the concept of a four-dimensional approach to ensuring sustainable development.
49
Pagès, Pierre-Benoit, Jonathan Cottenet, Anne-Sophie Mariet, Alain Bernard, and Catherine Quantin. "In-hospital mortality following lung cancer resection: nationwide administrative database." European Respiratory Journal 47, no. 6 (March 10, 2016): 1809–17. http://dx.doi.org/10.1183/13993003.00052-2016.
Full textAbstract:
Our aim was to determine the effect of a national strategy for quality improvement in cancer management (the “Plan Cancer”) according to time period and to assess the influence of type and volume of hospital activity on in-hospital mortality (IHM) within a large national cohort of patients operated on for lung cancer.From January 2005 to December 2013, 76 235 patients were included in the French Administrative Database. Patient characteristics, hospital volume of activity and hospital type were analysed over three periods: 2005–2007, 2008–2010 and 2011–2013.Global crude IHM was 3.9%: 4.3% during 2005–2007, 4% during 2008–2010 and 3.5% during 2011–2013 (p<0.01). 296, 259 and 209 centres performed pulmonary resections in 2005–2007, 2008–2010 and 2011–2013, respectively (p<0.01). The risk of death was higher in centres performing <13 resections per year than in centres performing >43 resections per year (adjusted (a)OR 1.48, 95% CI 1.197–1.834). The risk of death was lower in the period 2011–2013 than in the period 2008–2010 (aOR 0.841, 95% CI 0.764–0.926). Adjustment variables (age, sex, Charlson score and type of resection) were significantly linked to IHM, whereas the type of hospital was not.The French national strategy for quality improvement seems to have induced a significant decrease in IHM.
50
Rundall, Thomas G., Stephen M. Shortell, Janet C. Blodgett, Rachel Mosher Henke, and David Foster. "Adoption of Lean management and hospital performance: Results from a national survey." Health Care Management Review 46, no. 1 (July 9, 2020): E10—E19. http://dx.doi.org/10.1097/hmr.0000000000000287.
Full text